s many as 50,000 people in the US die of vaccinepreventable infections each year, primarily from influenza, pneumococcal disease, hepatitis B, and measles. 1 It is important to build immunization advocacy into continuous quality improvement processes in order to ensure that patient vaccine needs are understood.
As US health consumers become more educated regarding medical issues, some are voicing concern over the sources of biological products. For example, several vaccines, that in the past were made from egg or other tissue cultures, are now grown in cultures originally derived from human media. Depending on individual circumstances, this may concern patients and staff. There needs to be an increased awareness that these commercial alternatives do exist, although they are not always available in the US; that hospitals and health systems may make alternative vaccines available; and manufacturers should be encouraged to make more of these alternatives available.
A lack of available alternatives may be harmful, not only to some patients, but to the population in general. For example, some parents may choose not to have their children vaccinated, which puts both their children and, potentially, the population as a whole at increased risk for disease transmission. Acceptable alternative vaccines would eliminate this problem, and save these parents from the difficult dilemma of choosing whether or not to vaccinate.
Alternative vaccines are available for some diseases developed in animal cell or tissue. Patient risks may be different with these vaccines; however, those patients interested in an alternative may be willing to accept them. Availability of these vaccines varies among countries; there are no commercially available alternatives for vaccination against rubella, chickenpox, and hepatitis A in the US.
Some vaccines that are associated with embryonic cell cultures and, which might raise objections from some parents, patients, and medical staff, include Varivax 2 (chickenpox), Meruvax II 3 and MMR II 4 (rubella), Havrix 5 and VAQTA 6 (hepatitis A), Twinrix 7 (hepatitis A and B), and Imovax 8 (rabies).
There are alternatives available for some vaccines. In Japan and other countries, vaccines produced from non-human cell lines are available against rubella and hepatitis A. Therefore, the chickenpox vaccine is the only remaining issue for concerned patients in these countries.
Many of the medical advances of our day have been driven by similar concerns. For example, much of the work that has been done on plasma expanders and blood substitutes was, in part, stimulated by Jehovah's Witness patients' objection to receiving blood. Similarly, at least some of the use of beef insulin and the subsequent development of human insulin by recombinant DNA techniques were driven by those patients who had religious proscriptions against the use of pork-derived products.
In the current vaccine climate, it is important for us as pharmacists to recognize that some of our patients and staff have this opinion. It is, therefore, incumbent on us to do what is possible to make alternatives available, encourage the pharmaceutical industry to do so as well, and petition the FDA to process any such application expeditiously.
